SEL-302
- Generic Name
- SEL-302
- Drug Type
- Biotech
- Background
SEL-302 is a recombinant adeno-associated virus vector-based gene therapy expressing the methylmalonyl-CoA mutase (MMUT) transgene.
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05778877
- Locations
- 🇺🇸
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT03436732
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT02648269
- Locations
- 🇺🇸
Orlando Clinical Research Center, Inc., Orlando, Florida, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
🇺🇸SNBL Clinical Pharmacology Center Inc., Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath